16 results on '"pancreatology"'
Search Results
2. Early Enteral Nutrition in Paediatric Acute Pancreatitis—A Review of Published Studies.
- Author
-
Bukowski, Jan Stanisław, Dembiński, Łukasz, Dziekiewicz, Marcin, and Banaszkiewicz, Aleksandra
- Abstract
Nowadays, nutrition is said to be an integral aspect of acute pancreatitis (AP) treatment. Early enteral nutrition (EEN) is safe and beneficial for patients. This was confirmed by clinical experience and can be found in guidelines on managing adults with AP. Furthermore, paediatric recommendations encourage EEN use in AP. However, paediatric guidelines are based exclusively on studies in adults. Therefore, we present a review of published studies on the time of nutritional interventions in children with AP. A search was independently conducted in April 2022 by two of the authors. Only full-text papers published in English involving children between 0–21 were considered. Only four papers met our inclusion criteria: one randomised-control trial (RCT), one prospective study with retrospective chart review, and two retrospective chart reviews. All studies supported EEN and there was no recommendation of any delay in its initiation. The results of all four papers suggested EEN with a regular, normal-fat diet. EEN is safe in children with mild or moderately severe AP and may decrease the length of hospitalisation. Unfortunately, all the conclusions are based on a small amount of heterogeneous data that are mostly retrospective. Future prospective RCTs are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Very early and early nutrition in children with pancreatitis-A randomised trial.
- Author
-
Bukowski JS, Jamer T, Kowalska-Duplaga K, Marczuk M, Stelmaszczyk-Emmel A, Banasiuk M, and Banaszkiewicz A
- Subjects
- Humans, Male, Female, Child, Child, Preschool, Prospective Studies, Adolescent, Infant, C-Reactive Protein analysis, C-Reactive Protein metabolism, Poland, Severity of Illness Index, Biomarkers blood, Lipase blood, Acute Disease, Pancreatitis blood, Cytokines blood
- Abstract
Objectives: The aim of our study was to assess the impact of the very early introduction of refeeding on the course of acute pancreatitis (AP) in children. Additionally, we evaluated the effect of nutrition on inflammatory markers, including cytokines., Methods: This prospective randomised study was conducted in three university hospitals in Poland. Patients, aged 1-18 years with AP, were randomised into two groups: A-refeeding within 24 h of hospital admission (very early), and B-refeeding at least 24 h after admission (early nutrition). The severity of AP was assessed after 48 h. The serum concentrations of four cytokines (tumour necrosis factor α [TNFα], interleukin-1β [IL-1β], interleukin-6 [IL-6] and interleukin-8 [IL-8]) and C-reactive protein, as well as the activity of amylase, lipase and aminotransferases, were measured during the first 3 days of hospitalisation., Results: A total of 94 children were recruited to participate in the study. The statistical analysis included 75 patients with mild pancreatitis: 42-group A and 33-group B. The two groups did not differ in the length of hospitalisation (p = 0.22), AP symptoms or results of laboratory tests. Analysis of cytokine levels was conducted for 64 children: 38-group A and 26-group B. We did not find a difference in concentrations of the measured cytokines, except for IL-1β on the third day of hospitalisation (p = 0.01)., Conclusions: The time of initiation of oral nutrition within 24 h (very early) or after 24 h (early) from the beginning of hospitalisation had no impact on the length of hospitalisation, concentrations of TNF-α, IL-1β, IL-6 and IL-8, activity of amylase and lipase or occurrence of symptoms in children with mild AP., (© 2024 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.)
- Published
- 2024
- Full Text
- View/download PDF
4. Editorial: Hot Topics in Pancreatology From Europe-2020
- Author
-
Gabriele Capurso, Sebastien Gaujoux, and Enrique de-Madaria
- Subjects
pancreatology ,Pancreas 2000 ,mentoring ,European pancreatic club ,future ,Medicine (General) ,R5-920 - Published
- 2021
- Full Text
- View/download PDF
5. Early Enteral Nutrition in Paediatric Acute Pancreatitis—A Review of Published Studies
- Author
-
Jan Stanisław Bukowski, Łukasz Dembiński, Marcin Dziekiewicz, and Aleksandra Banaszkiewicz
- Subjects
early enteral nutrition ,pancreatology ,paediatric acute pancreatitis ,Nutrition. Foods and food supply ,TX341-641 - Abstract
Nowadays, nutrition is said to be an integral aspect of acute pancreatitis (AP) treatment. Early enteral nutrition (EEN) is safe and beneficial for patients. This was confirmed by clinical experience and can be found in guidelines on managing adults with AP. Furthermore, paediatric recommendations encourage EEN use in AP. However, paediatric guidelines are based exclusively on studies in adults. Therefore, we present a review of published studies on the time of nutritional interventions in children with AP. A search was independently conducted in April 2022 by two of the authors. Only full-text papers published in English involving children between 0–21 were considered. Only four papers met our inclusion criteria: one randomised-control trial (RCT), one prospective study with retrospective chart review, and two retrospective chart reviews. All studies supported EEN and there was no recommendation of any delay in its initiation. The results of all four papers suggested EEN with a regular, normal-fat diet. EEN is safe in children with mild or moderately severe AP and may decrease the length of hospitalisation. Unfortunately, all the conclusions are based on a small amount of heterogeneous data that are mostly retrospective. Future prospective RCTs are needed.
- Published
- 2022
- Full Text
- View/download PDF
6. Domestic scientists who made a significant contribution to the study of the digestive system diseases: images in art. Olexander Oleksiyovych Shalimov
- Subjects
абдомінальна хірургія ,клінічна школа ,наукова спадщина ,Olexander Oleksiyovych Shalimov ,O. O. Shalimov National Institute of Surgery and Transplantology of NAMS of Ukraine ,abdominal surgery ,панкреатологія ,angiosurgery ,clinical school ,pancreatology ,Національний інститут хірургії та трансплантології НАМН України імені О. О. Шалімова ,ангіохірургія ,scientific heritage ,Олександр Олексійович Шалімов - Abstract
Olexander Oleksiyovych Shalimov (1918—2006), Academician of the Academy of Sciences of the Ukrainian SSR, Hero of Socialist Labor, laureate of the State Awards of the USSR and the Ukrainian SSR, an Honorary Doctor of the RSFSR, an Honorary Scientist of the Ukrainian SSR, and afamous Soviet scientist and surgeon. He made agreat contribution to the development of scientific and practical surgery and to the training of highly qualified personnel.The years spent working in Kharkiv marked the beginning of O.O.Shalimov’s scientific career. The range of his research interests was unusually wide and covered the surgery of the digestive organs, the heart, the main vessels, anesthesiology, resuscitation, etc. Together with his students, he developed and improved techniques for surgical treatment of diseases of the esophagus, peptic ulcer of the stomach and duodenum, liver, and biliary tract. He developed and put into practice anumber of original techniques of surgical interventions, such as methods of esophagoplasty, pylorus‑preserving gastric resection, suturing of the duodenal stump, and rational methods of bile duct plastic surgery. O.O.Shalimov made aparticularly great contribution to pancreatic surgery. He proposed anew technique of pancreatoduodenal resection for pancreatic cancer and anumber of surgeries for the treatment of various forms of chronic pancreatitis.The Kyiv period of O.O.Shalimov’s life was characterized by further in‑depth study of diseases of the digestive and cardiovascular systems and the development of methods for their surgical treatment, the widespread introduction of the results of scientific developments into healthcare practice, and active work to improve surgical care for the population of the republic. The Institute headed by him (the leading institution in the republic in the field of surgery) had become not only one of the leading surgical institutions in the state but also aschool of highly qualified personnel and amedical advisory, organizational, and methodological center of Ukraine. Theresult of the activity of O.O.Shalimov is that Ukraine has become aleader in the application of organ‑preserving surgeries at present.The works by O.O.Shalimov on pancreatic surgery are of particular interest. For many years, this organ was considered inaccessible to surgeons, since the resulting complications, as arule, nullified all the efforts of surgeons. O.O.Shalimov was one of the path‑breakers in the development of techniques for the surgical treatment of pancreatic diseases. He devoted more than four decades to this work, achieving significant success and gaining high prestige as apancreatic surgeon. The research results by O.O.Shalimov are reflected in 712 publications, including 24 monographs and three atlases. He was the author of 92 inventions. There are more than 40 doctors and 80 candidates of sciences among the numerous students of O.O.Shalimov., Олександр Олексійович Шалімов (1918—2006)— академік АН УРСР, Герой Соціалістичної Праці, лауреат державних премій СРСР та УРСР, заслужений лікар РРФСР, заслужений діяч науки УРСР, відомий радянський вчений‑хірург. Зробив великий внесок урозвиток наукової іпрактичної хірургії та підготовку висококваліфікованих кадрів.Роки роботи уХаркові були періодом становлення Олександра Олексійовича як вченого. Коло його наукових інтересів надзвичайно широке та охоплює питання хірургії органів травлення, серця, магістральних судин, анестезіології, реаніматології тощо. Разом зі своїми учнями він займався розробкою та вдосконаленням методів хірургічного лікування захворювань стравоходу, виразкової хвороби шлунка ідванадцятипалої кишки, печінки, жовчовивідних шляхів. Він розробив та впровадив упрактику низку оригінальних методик оперативних втручань, зокрема способи езофагопластики, резекції шлунка зі збереженням воротаря, ушивання кукси дванадцятипалої кишки, атакож раціональні способи пластики жовчних проток. Особливо великий внесок О.О.Шалімов зробив ухірургію підшлункової залози. Він запропонував нову методику панкреатодуоденальної резекції при раку підшлункової залози та низку хірургічних операцій для лікування різних форм хронічного панкреатиту.Київський період діяльності Олександра Олексійовича характеризується подальшим глибоким вивченням захворювань органів травної та серцево‑судинної систем ірозробкою методів їхнього хірургічного лікування, широким впровадженням результатів наукових розробок упрактику охорони здоров’я, активною діяльністю щодо вдосконалення хірургічної допомоги населенню республіки. Керований ним Київський НДІ клінічної та експериментальної хірургії МОЗ УРСР— головна установа вреспубліці зпроблеми «Хірургія»— став не лише однією зпровідних хірургічних установ країни, ай школою кадрів найвищої кваліфікації, лікувально‑консультативним та організаційно‑методичним центром України. Результатом діяльності О.О.Шалімова єте, що нині Україна стала лідером узастосуванні органощадних операцій.Особливий інтерес становлять роботи Олександра Олексійовича, присвячені хірургії підшлункової залози. Багато років цей орган вважали недоступним для хірургів, оскільки серйозні ускладнення зазвичай зводили нанівець усі їхні зусилля. О.О.Шалімов— один із піонерів урозробці способів хірургічного лікування захворювань підшлункової залози. Він присвятив цій роботі понад чотири десятиліття, досягнувши значних успіхів іздобувши авторитет як хірург‑панкреатолог. Результати наукових пошуків Олександра Олексійовича відображено у712 публікаціях, зокрема у24 монографіях ітрьох атласах. Він автор 92 винаходів. Серед численних учнів О.О.Шалімова понад 40 докторів та 80 кандидатів наук.
- Published
- 2023
7. Acute Pancreatitis in COVID-19-associated Multisystem Inflammatory Syndrome of Children-A Single Center Experience
- Author
-
Bhaswati C Acharyya, Monideepa Dutta, Saumen Meur, Dhritabrata Das, and Saumyabrata Acharyya
- Subjects
SARS-CoV-2 ,Pancreatology ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,pancreatitis ,COVID-19 ,Original Article ,multisystem inflammatory syndrome in children - Abstract
Supplemental Digital Content is available in the text., Objectives: A multisystem inflammatory syndrome in children (MIS-C) was identified as an entity temporally associated with the present COVID-19 pandemic. This inflammatory syndrome affects various organ systems including the gastrointestinal and hepatobiliary systems. The following study was undertaken to primarily detect the fraction of children who had pancreatitis as major organ involvement during the development of MIS-C. The secondary objective was to evaluate their clinical and investigational profile as well as the outcome of management. Methods: A retrospective chart analysis of all children admitted in a tertiary pediatric center from April to December 2020, diagnosed as COVID-19 associated MIS-C, was done. Those presenting with acute pancreatitis were detected and detailed clinical features, investigations, treatments, as well as outcomes, were recorded. Results: A total of 17 children were diagnosed as MIS-C associated with SARS-CoV-2 in the above-mentioned period. Among them, 9 (53%) children had pancreatitis right from the start of the illness; 5 (56%) children with pancreatitis presented with shock. A very high CRP and cardiac involvement were observed in all. A severe reduction of myocardial contractility was associated with poor outcomes. Necrotic pancreatitis was not noted in any of them. A mortality of 22% was documented in this group and a 3-month outcome among those who survived displayed complete resolution of all cardiac as well as pancreatic abnormalities. Conclusion: Acute pancreatitis can be an essential cause of abdominal symptoms in COVID-19-related MIS-C. Pancreatitis may be considered to be one of the parameters in the diagnostic criteria of MIS-C.
- Published
- 2021
8. Editorial: Hot Topics in Pancreatology From Europe-2020
- Author
-
Enrique de-Madaria, Gabriele Capurso, and Sébastien Gaujoux
- Subjects
future ,Medicine (General) ,business.industry ,mentoring ,General Medicine ,Editorial ,R5-920 ,Hot topics ,pancreatology ,European pancreatic club ,Medicine ,Pancreas 2000 ,business - Published
- 2021
9. Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease Worsen the Outcome in Acute Pancreatitis: A Systematic Review and Meta-Analysis
- Author
-
Dávid Németh, Dániel Pécsi, Adrienn Erős, Bálint Erőss, Péter Hegyi, Péter Jeno Hegyi, Zsolt Szakács, Alexandra Mikó, Szilárd Váncsa, and Gabriella Pár
- Subjects
medicine.medical_specialty ,acute pancreatitis ,lcsh:Medicine ,Disease ,Review ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,business.industry ,lcsh:R ,Fatty liver ,non-alcoholic fatty liver disease ,General Medicine ,Odds ratio ,Hepatology ,medicine.disease ,Confidence interval ,030220 oncology & carcinogenesis ,Meta-analysis ,hepatology ,pancreatology ,Acute pancreatitis ,fatty liver disease ,030211 gastroenterology & hepatology ,prognosis ,business ,Cohort study - Abstract
The prevalence of fatty liver disease (FLD) and that of non-alcoholic fatty liver disease (NAFLD) share some risk factors known to exacerbate the course of acute pancreatitis (AP). This meta-analysis aimed to investigate whether FLD or NAFLD carry a higher risk of untoward outcomes in AP. In accordance with PRISMA guidelines, we performed a systematic search in seven medical databases for cohort studies that compared the outcomes of AP for the presence of FLD or NAFLD, and we calculated pooled odds ratio (OR) or weighted mean difference (WMD) with 95% confidence interval (CI). We included 13 articles in our meta-analysis. AP patients with FLD were more likely to die (5.09% vs 1.89%, OR = 3.56, CI = 1.75–7.22), develop severe AP (16.33% vs 7.87%, OR = 2.67, CI = 2.01–3.56), necrotizing pancreatitis (34.83% vs 15.75%, OR = 3.08, CI = 2.44–3.90) and had longer in-hospital stay (10.8 vs 9.2 days, WMD = 1.46, OR = 0.54–2.39). Patients with NAFLD were more likely to have severe AP and longer hospital stay. Both FLD and NAFLD proved to be independent risk factors of a more severe disease course (OR = 3.68, CI = 2.16–6.29 and OR = 3.39, CI = 1.52–7.56 for moderate/ severe vs. mild AP, respectively). FLD and NAFLD worsen the outcomes of AP, which suggests that incorporating FLD or NAFLD into prognostic scoring systems of AP outcomes might improve the prediction of severity and contribute to a more individualized patient care.
- Published
- 2020
10. Improving outcomes for operable pancreatic cancer: Is access to safer surgery the problem?
- Author
-
Chang, David K., Merrett, Neil D., and Biankin, Andrew V.
- Subjects
- *
PANCREATIC cancer treatment , *OPERATIVE surgery , *GENERAL practitioners , *NIHILISM , *MORTALITY , *HEALTH outcome assessment - Abstract
Despite advances in the understanding and treatment of pancreatic cancer in the last two decades, there is a persisting nihilistic attitude among clinicians. An alarmingly high rate of under-utilization of surgical management for operable pancreatic cancer was recently reported in the USA, where more than half of patients with stage 1 operable disease and no other contraindications were not offered surgery as therapy, denying this group of patients a 20% chance of long-term survival. These data indicate that a nihilistic attitude among clinicians may be a significant and reversible cause of the persisting high mortality of patients with pancreatic cancer. This article examines the modern management of pancreatic cancer, in particular, the advances in surgical care that have reduced the mortality of pancreatectomy to almost that of colonic resection, and outlines a strategy for improving outcomes for patients with pancreatic cancer now and in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
11. The future of pancreatology: how to go where we have never been before
- Author
-
Urrutia, Raul
- Subjects
- *
MOLECULAR biology , *BIOLOGY , *CYTOLOGY , *GENOMICS - Abstract
Abstract: The current article is part of a series of manuscripts, which together serve as a never-perfect yet candid attempt to honor the remarkable scientific stature of Professor Hans Gunther Beger. The challenge posed to the author has been to meditate on the future of pancreatology. In the following paragraphs, to the exclusion of no other, we provide an approach to future discoveries in our field. This approach combines the large scope of the new biology (eg, genomics) with the analytical power of conventional, hypothesis-driven, molecular cell biology of individual laboratories to build comprehensive functional models of normal and diseased pancreatic cell populations. In addition, the potential challenges that both the size of our field and current research funding offer to scientists focused on the pancreas are discussed. It is the author’s hope that the readers will not only meditate on the reflections offered here but, when in agreement with the positions stated, will help to implement a road map that can make our scientific field better. Never forget—the lives of our patients depend on what we do. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
12. Proteomics in Pancreatic Disease.
- Author
-
Löhr, Matthias and Faissner, Ralf
- Abstract
Proteomics represents a novel methodological approach to investigate the expression of all proteins by a cell or organism in its entireness, similar to global strategies for DNA (genomics) and RNA (transcriptomics). This review focuses on the history of protein analysis, which made up the golden age of pancreatic physiology, the current methodology for proteomics (2D gel electrophoresis, mass spectrometry) and the few published experiences with proteomics in the field of pancreatology until now. Finally, potential applications of proteomics for the pancreas, in concert with other techniques, are cited. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
13. The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, Ca 19-9, Ca 125, Ca 15-3.
- Author
-
Bassi, Claudio, Salvia, Roberto, Gumbs, Andrew A., Butturini, Giovanni, Falconi, Massimo, and Pederzoli, Paolo
- Subjects
TUMORS ,BLOOD plasma ,TUMOR markers ,BIOMARKERS ,DIAGNOSIS ,CYSTS (Pathology) ,ONCOLOGY - Abstract
Background. Differentiating between mucinous cystic tumors (MCTs) and serous cystic tumors (SCTs) can be a troubling diagnostic dilemma in pancreatology: when SCTs present in their macro-oligocystic form they must be resected because MCT cannot be ruled out, and some tumors considered benign are actually MCTs, which delays diagnosis and places patients at increased risk. Examination of preoperative serum tumor markers may help improve preoperative diagnosis. Materials and methods. The tumor markers CEA, Ca 19-9, Ca 125, and Ca 15-3 were examined in 157 patients with SCTs or MCTs. Results. Positive CEA marker status is an indicator of an MCT, although sensitivity is low at 17%. Using three serum tumor markers (CEA, Ca 19-9, and Ca 125), 27% of MCTs were found to have two or more markers positive, compared to none for the SCTs. Sensitivity decreases to 13% for differentiating benign MCTs from benign SCTs but specificity remains 100%. Conclusions. In the differential diagnosis of SCTs vs. MCTs no reliable serum tumor marker exists which can diagnose SCTs and spare some patients unnecessary operations. Nonetheless, positive CEA serum marker status and or the presence of more than two positive serum markers (CEA, Ca 19-9, or Ca 125) indicates the presence of an MCT and can prevent delay in diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
14. Case Report: Acute Abdominal Pain as Presentation of Pneumonia and Acute Pancreatitis in a Pediatric Patient With COVID-19
- Author
-
Cheryl E. Gariepy, Karla Vaz, W. Garrett Hunt, Raul E. Sanchez, Ethan A. Mezoff, and Colleen B. Flahive
- Subjects
Pediatrics ,medicine.medical_specialty ,Abdominal pain ,acute pancreatitis ,pediatrics ,SARS-CoV-2 ,business.industry ,Nausea ,Case Report ,Disease ,medicine.disease ,Pneumonia ,Pancreatology ,medicine ,Vomiting ,Acute pancreatitis ,Pancreatitis ,medicine.symptom ,Presentation (obstetrics) ,business - Abstract
Abdominal pain, nausea, and vomiting are known gastrointestinal symptoms of symptomatic SARS-CoV-2 infection (COVID-19 disease) in pediatric patients.(1) There is little literature regarding pancreatitis in COVID-19. We describe a 16-year-old male diagnosed with acute pancreatitis in the setting of a SARS-COV-2 infection and associated fluid balance considerations.
- Published
- 2020
15. Editorial: Hot Topics in Pancreatology From Europe-2020.
- Author
-
Capurso G, Gaujoux S, and de-Madaria E
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past co-authorship with the author Ed-M.
- Published
- 2021
- Full Text
- View/download PDF
16. Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease Worsen the Outcome in Acute Pancreatitis: A Systematic Review and Meta-Analysis.
- Author
-
Váncsa, Szilárd, Németh, Dávid, Hegyi, Péter, Szakács, Zsolt, Hegyi, Péter Jeno, Pécsi, Dániel, Mikó, Alexandra, Erőss, Bálint, Erős, Adrienn, and Pár, Gabriella
- Subjects
- *
FATTY liver , *NECROTIZING pancreatitis , *DISEASE progression , *META-analysis , *PANCREATITIS - Abstract
The prevalence of fatty liver disease (FLD) and that of non-alcoholic fatty liver disease (NAFLD) share some risk factors known to exacerbate the course of acute pancreatitis (AP). This meta-analysis aimed to investigate whether FLD or NAFLD carry a higher risk of untoward outcomes in AP. In accordance with PRISMA guidelines, we performed a systematic search in seven medical databases for cohort studies that compared the outcomes of AP for the presence of FLD or NAFLD, and we calculated pooled odds ratio (OR) or weighted mean difference (WMD) with 95% confidence interval (CI). We included 13 articles in our meta-analysis. AP patients with FLD were more likely to die (5.09% vs 1.89%, OR = 3.56, CI = 1.75–7.22), develop severe AP (16.33% vs 7.87%, OR = 2.67, CI = 2.01–3.56), necrotizing pancreatitis (34.83% vs 15.75%, OR = 3.08, CI = 2.44–3.90) and had longer in-hospital stay (10.8 vs 9.2 days, WMD = 1.46, OR = 0.54–2.39). Patients with NAFLD were more likely to have severe AP and longer hospital stay. Both FLD and NAFLD proved to be independent risk factors of a more severe disease course (OR = 3.68, CI = 2.16–6.29 and OR = 3.39, CI = 1.52–7.56 for moderate/ severe vs. mild AP, respectively). FLD and NAFLD worsen the outcomes of AP, which suggests that incorporating FLD or NAFLD into prognostic scoring systems of AP outcomes might improve the prediction of severity and contribute to a more individualized patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.